



## Pfizer Quality Improvement RFP

### INNOVative Multi-disciplinary Clinical Management of Inflammatory Diseases

#### 2023 IT INNOVA-MIND

##### **Competitive Grant Program – using Expert Review Panel**

*Pfizer Global Medical Grants (GMG) supports the global healthcare community's independent initiatives (e.g., research, quality improvement or education) to improve patient outcomes in areas of unmet medical need that are aligned with Pfizer's medical and/or scientific strategies.*

*Pfizer's GMG competitive grant program involves a publicly posted Request for Proposal (RFP) that provides detail regarding a specific area of interest, sets timelines for review and approval, and uses an expert review panel (ERP) to make final grant decisions. Organizations are invited to submit an application addressing the specific gaps in practice as outlined in the specific RFP.*

*For all quality improvement grants, the grant requester (and ultimately the grantee) is responsible for the design, implementation, and conduct of the independent initiative supported by the grant. Pfizer must not be involved in any aspect of project development, nor the conduct or monitoring of the quality improvement program.*

### Overview

Pfizer is launching a competitive grant program seeking to support Quality Improvement projects that will implement strategies measurably improving the quality of care and best practices around the management of adults patients with Atopic Dermatitis (AD), Rheumatoid Arthritis (RA), Psoriatic Arthritis (PsA), Ankylosing Spondylitis (AS) and Ulcerative Colitis (UC).

The intent of this RFP is to encourage proposals for the implementation of multi-disciplinary team care models

### Geographic Scope Italy

### Project Types and Area of Interest

Potential applicants are encouraged to propose multi-disciplinary team projects focused on improving the quality of patient care, the outcomes and prognosis of adult patients eligible for advanced therapies (i.e. biologic drugs, small molecules), with one or more of the following autoimmune inflammatory diseases: Atopic Dermatitis (AD), Rheumatoid Arthritis (RA), Psoriatic Arthritis (PsA), Ankylosing Spondylitis (AS), Ulcerative Colitis (UC) and any related comorbidities and/or risk factors; cross-indication projects are allowed.

### Key Milestones

- Date RFP Issued: **March 7, 2023**
- Application submission deadline: **April 27, 2023**
- Anticipated decision notification date: **June 30, 2023**
- Anticipated project start date : **From October 2023**

### Link to full RFP

[INNOVative Multi-disciplinary Clinical Management of Inflammatory Diseases, 2023 IT INNOVA-MIND](#)